Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Decrease in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totaling 46,578 shares, a decline of 34.0% from the March 31st total of 70,605 shares. Based on an average daily volume of 123,536 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.1% of the shares of the company are sold short.

Dogwood Therapeutics Stock Up 5.9%

Shares of DWTX stock traded up $0.08 during trading hours on Thursday, reaching $1.43. 48,626 shares of the company’s stock were exchanged, compared to its average volume of 76,367. Dogwood Therapeutics has a fifty-two week low of $1.28 and a fifty-two week high of $9.50. The stock has a market capitalization of $47.76 million, a P/E ratio of -0.08 and a beta of 2.05. The business has a fifty day moving average price of $2.33 and a 200-day moving average price of $3.93.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.96. As a group, research analysts expect that Dogwood Therapeutics will post -0.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on DWTX. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a report on Monday. Weiss Ratings lowered Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.